12:00 AM
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RXI-109: Phase I data

Data from 15 patients scheduled to undergo an elective abdominoplasty in a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial showed that single intradermal injections of RXI-109 at the incision sites were well tolerated with no serious local or systemic side effects reported. Local erythema...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >